Troy Wichterman Sells 588 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 588 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $20.74, for a total transaction of $12,195.12. Following the transaction, the chief financial officer directly owned 220,649 shares in the company, valued at approximately $4,576,260.26. This represents a 0.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, January 6th, Troy Wichterman sold 990 shares of BioLife Solutions stock. The stock was sold at an average price of $25.59, for a total transaction of $25,334.10.
• On Tuesday, December 9th, Troy Wichterman sold 1,033 shares of BioLife Solutions stock. The stock was sold at an average price of $25.13, for a total transaction of $25,959.29.

BioLife Solutions Stock Down 1.3%

NASDAQ BLFS opened at $19.86 on Friday. The company has a 50-day simple moving average of $23.37 and a two-hundred day simple moving average of $25.07. BioLife Solutions, Inc. has a 12-month low of $19.10 and a 12-month high of $29.62. The firm has a market cap of $959.24 million, a price-to-earnings ratio of -180.53 and a beta of 1.90.

Analysts Set New Price Targets

BLFS has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, January 21st. Zacks Research upgraded shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. Wall Street Zen raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Northland Securities set a $34.00 price objective on shares of BioLife Solutions in a research report on Monday, January 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of BioLife Solutions in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, BioLife Solutions presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

BioLife Solutions News Roundup

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Analyst/preview: Seeking Alpha highlights BioLife’s strategic refocus on core biopreservation media and vials, forecasting ~17–20% revenue growth in FY2026, positive GAAP net income and mid‑60s gross margins; cites the PanTHERA acquisition and a QKine partnership as drivers of higher ARPU and next‑gen product launches by late‑2026. BioLife Looks Strong For Fiscal Year 2026
• Positive Sentiment: Company presentation/press release: BioLife reiterated its growth and strategic refocus in a recent presentation, reinforcing management’s turnaround narrative and the FY26 outlook that underpins the Seeking Alpha preview. BioLife Solutions Highlights Growth and Strategic Refocus in Presentation
• Neutral Sentiment: Short‑interest data published for early March shows zero shares / 0.0 days‑to‑cover — this appears erroneous or non‑informative and does not indicate material short pressure at present. MarketBeat BLFS
• Negative Sentiment: Insider selling: Multiple senior executives (CFO, CMO, EVP, CTO and others) disclosed modest open‑market sales (hundreds of shares apiece at ≈$20.74). Amounts are small relative to their holdings, but clustered sales can trigger short‑term headline risk and investor caution. Insider trading alert

Hedge Funds Weigh In On BioLife Solutions

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Global Retirement Partners LLC bought a new stake in BioLife Solutions in the fourth quarter valued at $30,000. Kemnay Advisory Services Inc. bought a new position in BioLife Solutions in the 4th quarter worth $35,000. Hantz Financial Services Inc. lifted its position in shares of BioLife Solutions by 54.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 659 shares during the period. Quarry LP lifted its position in shares of BioLife Solutions by 50.9% in the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 713 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 441 shares in the last quarter. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.